27-Year-Old Man Presents With an Anterior Mediastinal Mass

Safety data from the phase 2 LITESPARK-003 trial evaluating belzutifan/cabozantinib in renal cell carcinoma show no treatment-related deaths.

Authors of an article published in ONCOLOGY® detail how a novel multidisciplinary lifestyle medicine clinic can meet the needs of cancer survivors.

Phase 1 data support the fast track designation for invikafusp alfa in advanced colorectal cancer with high tumor mutational burden.

Oncologists discuss data from the NETTER-1 and NETTER-2 trials and the extent to which they support the applicability of 177Lu-dotatate in NETs.

Subcutaneous isatuximab yields noninferior results vs intravenous isatuximab when paired with pomalidomide and dexamethasone in the phase 3 IRAKLIA trial.

The phase 3 NIVOPOSTOP GORTEC 2018-01 trial shows that nivolumab added to radiotherapy and cisplatin had improved efficacy over SOC treatments in SCCHN.